A cool approach to reducing electrode-induced trauma: Localized therapeutic hypothermia conserves residual hearing in cochlear implantation.
Ilmar Tamames, Curtis King, Esperanza Bas...
https://pubmed.ncbi.nlm.nih.gov/27260269/Actively Recruiting
Led by Restorear Devices LLC · Updated on 2026-07-28
80
Participants Needed
1
Research Sites
22 weeks
Total Duration
Researchers are evaluating the use of mild therapeutic hypothermia MTH devices to relieve symptoms of chronic tinnitus, a condition characterized by the perception of sound without an external source. This study focuses on assessing the effects of MTH on tinnitus severity and the comfort and acceptability of the therapy device. Tinnitus affects quality of life, including sleep, mood, and concentration, and current treatments often do not address underlying causes or provide widespread relief. Participants will wear a headband-style device, called ReBound, designed to deliver cooling therapy to the inner ear for a single 30-minute session at home. The study includes two groups one receiving the mild therapeutic hypothermia treatment and the other using a sham placebo device. Researchers will compare tinnitus severity and patient comfort between groups, monitoring any adverse events such as vestibular activation or skin issues. Participants will complete questionnaires before and after the treatment session, as well as 24 hours later, to assess tinnitus severity and symptom changes. They will also complete a device acceptance questionnaire regarding comfort and ease of use. The study is conducted entirely remotely, with subjective assessments collected online. Safety monitoring includes evaluating potential side effects, and the trial is designed to explore a non-invasive, accessible treatment option for tinnitus over a short participation period.
CONDITIONS
External Therapy for Tinnitus Management
K
Kendall Stern, MPH
S
Suhrud Rajguru, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Restorear Devices LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Cold pack-delivered mild therapeutic hypothermia | Sham device (placebo) |
|---|---|---|
| What is it? | A headband-style device delivers mild therapeutic hypothermia (cooling) non-invasively to the structures of the inner ear for 30 minutes. | A headband-style device is worn for 30 minutes, but delivers no active cooling. Participants are told they are receiving therapy. |
| Role in this trial | Participants in this group receive the investigational cooling therapy to assess its impact on tinnitus severity. | Participants in this group receive a sham (inactive) device, serving as the placebo control to compare with the investigational therapy. |
| Primary use/purpose | Studied for its potential to reduce subjective tinnitus severity through local cooling of the cochlea. | Used as a placebo to help determine whether the investigational device offers benefit beyond expectation. |
| How is it given or performed? | The cooling device is worn as a headband and delivers mild hypothermia for 30 minutes. The approach is non-invasive. | Participants wear a similar headband device for 30 minutes, but it does not deliver active cooling. |
| Evidence status | There is ongoing clinical investigation; results for this device in tinnitus are not yet established. Preclinical and early studies suggest cooling may help protect cochlear structures in other situations, but direct human tinnitus outcomes remain unproven. | A sham device is expected to provide no specific effect on tinnitus but helps control for placebo response in clinical trials. |
| Important limitations | There are no published results in human tinnitus, and this approach remains investigational. Preclinical studies do not guarantee efficacy or safety for reducing tinnitus symptoms in adults. | Expected to have no effect on tinnitus severity; placebo effect and patient expectations cannot be excluded. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 remote visit
Duration - Single 30-minute session
Participants wear the headband-style device for a single 30-minute session at home, receiving either the mild therapeutic hypothermia or sham treatment.
Remote assessments before and after treatment
Duration - 24 hours post-treatment
Participants complete questionnaires immediately after treatment and 24 hours later to assess changes in tinnitus severity and device comfort.
Remote questionnaire completion
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ilmar Tamames, Curtis King, Esperanza Bas...
https://pubmed.ncbi.nlm.nih.gov/27260269/J Lamprecht, C Morgenstern
https://pubmed.ncbi.nlm.nih.gov/3968937/Samantha Rincon Sabatino, Andrea Rivero, Rachele Sangaletti...
https://pubmed.ncbi.nlm.nih.gov/38292902/Kenneth R Henry
https://pubmed.ncbi.nlm.nih.gov/12742241/M C Liberman, L W Dodds
https://pubmed.ncbi.nlm.nih.gov/6511672/David Baguley, Don McFerran, Deborah Hall
https://pubmed.ncbi.nlm.nih.gov/23827090/Jacqueline Sheldrake, Peter U Diehl, Roland Schaette
https://pubmed.ncbi.nlm.nih.gov/26029161/F Meisel-Mikolajczyk, E Swoboda-Kopeć, M Skośkiewicz
https://pubmed.ncbi.nlm.nih.gov/896576/K R Henry, R A Chole
https://pubmed.ncbi.nlm.nih.gov/6401081/Ilmar Tamames, Curtis King, Chin-Yuh Huang...
https://pubmed.ncbi.nlm.nih.gov/29240567/Restorear Devices LLC
Lead Sponsor